Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-04-28 Annual Report
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Appointment
Annual Report Classification · 95% confidence The document is a detailed announcement of the outcome of a board meeting held on 28th April 2026 by Piramal Pharma Limited. It includes approval of audited financial results for the fiscal year ended 31st March 2026, re-appointments of directors and key managerial personnel, and change of registered office address. The document contains the audited financial results and the statutory auditors' report with an unmodified opinion, which are substantive financial disclosures. It also includes detailed profiles of directors and key personnel. The document is lengthy (15,000 characters) and contains actual financial data and management decisions, not just an announcement or a certification. The primary focus is on the audited financial results for the full fiscal year, which aligns with an Annual Report (10-K) type filing. However, since it is not the full annual report but the audited financial results and related board meeting outcome, it is best classified as an Annual Report (10-K) equivalent filing in the Indian context, as it covers the full fiscal year audited results and related disclosures. Therefore, the filing type is 10-K with high confidence. FY 2026
2026-04-28 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the audited financial results (standalone and consolidated) for the quarter and full year ended 31 March 2026. It includes detailed financial highlights, business segment performance, consolidated profit and loss statement, balance sheet, and key business updates. It also contains an invitation to an earnings conference call to discuss these results. The document is comprehensive and contains substantive financial data and analysis for the quarter and full year, which aligns with the characteristics of an Interim / Quarterly Report (IR). Although it covers a full fiscal year, it is not a full Annual Report (10-K) but rather a quarterly and full-year financial results announcement with detailed financial statements and management commentary. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). FY 2026
2026-04-28 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the audited financial results (standalone and consolidated) for the quarter and full year ended 31 March 2026. It includes detailed financial highlights, business segment performance, consolidated profit and loss statement, balance sheet, and key business updates. The document also contains an invitation to an earnings conference call to discuss these results. The presence of detailed financial data and analysis for the quarter and full year indicates this is a comprehensive financial report for a period shorter than a full fiscal year (quarterly and annual combined). However, since it is primarily focused on quarterly and full-year results with detailed financial statements and analysis, it fits best under the category of Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it lacks the full scope and length of an annual report, nor is it just an earnings release (ER) which typically contains only key highlights without detailed financial statements. The inclusion of an investor presentation alongside the press release supports the IR classification rather than just an investor presentation (IP) alone. Therefore, the most appropriate classification is IR with high confidence. FY 2026
2026-04-28 English
Cessation
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Piramal Pharma Limited dated 28th April 2026, reporting the outcome of a Board Meeting. It includes approval of audited financial results for the fiscal year ended 31st March 2026, re-appointments of directors and key managerial personnel, and a change in registered office address. The document references compliance with SEBI Listing Regulations and includes auditor's declaration with unmodified opinion. It contains detailed profiles of directors and key personnel, indicating it is a comprehensive disclosure. The document is not merely announcing the availability of a report but includes substantive information about financial results approval and board decisions. The primary focus is on board decisions including financial results approval and management changes. This fits best under Board/Management Information (MANG) as it announces board meeting outcomes, director re-appointments, and key managerial personnel changes. Although it mentions audited financial results, it does not contain the full financial statements or detailed financial analysis itself, so it is not an Annual Report (10-K) or Audit Report (AR). It is also not a Regulatory Filing (RNS) as it is a formal board meeting outcome announcement with multiple management and governance updates. Therefore, the classification is MANG with high confidence.
2026-04-28 English
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Piramal Pharma Limited dated 28th April 2026, reporting the outcome of a Board Meeting. It includes approval of audited financial results for the fiscal year ended 31st March 2026, re-appointments of directors and key managerial personnel, and changes in registered office address. The document references compliance with SEBI Listing Regulations and includes auditor's declaration with unmodified opinion. It contains detailed profiles of directors and KMP appointments. The document is not the full annual report or financial statements but an official announcement of board decisions including financial results approval and management changes. It is not a standalone audit report, earnings release, or proxy solicitation. The primary content is the outcome of the board meeting including management appointments and financial results approval. Therefore, the best fitting category is Board/Management Information (MANG).
2026-04-28 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Piramal Pharma Limited dated 28th April 2026, reporting the outcome of a Board Meeting. It includes approval of audited financial results for the fiscal year ended 31st March 2026, re-appointments of directors and key managerial personnel, and a change in registered office address. The document contains actual financial results (audited standalone and consolidated financial statements) and the statutory auditor's report with an unmodified opinion. It also includes detailed profiles of directors and key personnel appointments. The presence of audited financial statements and auditor's report for the full fiscal year indicates this is a full annual financial report rather than a mere announcement or certification. The document is comprehensive and over 15,000 characters, so it is not a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent) as it covers the full financial year, includes audited financial statements, auditor's report, and detailed management and board information. Hence, the correct classification is Annual Report (10-K). FY 2026
2026-04-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.